- Company
- Competition in the narcolepsy tx market is expected
- by Eo, Yun-Ho Feb 3, 2022 05:56am
- Competition for prescription of drugs that prevent sleepiness and manage so-called narcolepsy has begun. According to related industries, competition with Teva Handok's Nuvigil (Armodafinil) is expected as Wakix (Pitolisant) of Mitsubishi Tanabe Pharma will be applied from next month (February). Wakix is a counteractive and antagonist that se
- Company
- An unexpected story by Organon and Viatris
- by Jan 28, 2022 05:58am
- Organon and Viatris' patent expired drugs remain powerful. Although questions have been raised about the growth engines of the two independent corporations after receiving "old drugs" from MSD and Pfizer, it is evaluated that it is as good as in Korea. ◆Organon's Atozet and Cozaar's outpatient prescription is 250 billion won Accordi
- Opinion
- [Reporter’s View] Ahead Kymriah’s NHIS negotiations
- by Eo, Yun-Ho Jan 28, 2022 05:57am
- Only the National Health Insurance Service left to go, the ultra-high-priced novel CAR-T therapy ‘Kymriah (tisagenlecleucel)’ passed all the steps necessary for insurance benefit. In other words, the fate of Kymriah’s reimbursement now lies The fate of Kymriah’s reimbursement, a drug that costs around &8361;500 million for a singl
- Policy
- Publicized discussion on PAH reimbursement bears fruit
- by Choi-sun Jan 28, 2022 05:57am
- The issue regarding reimbursement standards set for pulmonary arterial hypertension drugs finally bore fruit three years after experts in Korea including the Korean Society of Cardiology, Korean Pulmonary Hypertension Society, The Korean Society of Hypertension, and The Korean Academy of Tuberculosis and Respiratory Diseases publicized the i
- Policy
- Generics for Galvus will be listed next month
- by Kim, Jung-Ju Jan 28, 2022 05:57am
- Generics, which had patent disputes with Galvus, a DPP-4 inhibitor-based diabetes treatment, will be listed in earnest next month. This is because companies applied for a change in permit conditions and the MFDS approved it, making it possible to sell it immediately. According to the industry, the MOHW is pushing for a revision (proposal) of
- Company
- The NOAC market with ₩230 billion is fluctuating
- by Kim, Jin-Gu Jan 27, 2022 05:44am
- The NOAC market, which has grown to 230 billion won, has fluctuated due to generic drugs. After the Supreme Court ruling, Eliquis enjoyed reflective benefits as generics were withdrawn altogether. On the other hand, in the case of Xarelto, as generic products were released one after another due to the expiration of material patents, it seems
- Policy
- MNCs ask to “Innovate new drug reimbursement environment"
- by Lee, Jeong-Hwan Jan 27, 2022 05:43am
- The key content of the policy proposal that representatives of multinational pharmaceutical companies with branches in Korea presented to the People Power Party’s election campaign committee was that the government should establish or improve the National Health Insurance and drug pricing system to encourage the use of highly effective but
- Company
- Celltrion completes transfer of Takeda-acquired products
- by Ji Yong Jun Jan 27, 2022 05:43am
- The transfer of rights for Takeda Pharmaceutical’s products that Celltrion acquired is now complete. The license of OTCs and diabetes drugs that were sold under Takeda Pharmaceutical’s name has been changed to Celltrion Pharm. According to the industry on the 26th, the ownership of the license for Nesina Act Tab 12.5/30mg has been chang
- Policy
- PVA guidelines are about to be revised
- by Lee, Hye-Kyung Jan 27, 2022 05:43am
- The NHIS is internally reviewing a revision to the guidelines that includes a 100 → 90% change in the arithmetic average exclusion standard and a 15 → 2 billion won increase in the claim exclusion standard from this year's "Type Da" negotiations. NHIS' Senior director Lee Sangil said at the Korea Special Press Association briefing held o
- Policy
- The NHIS will begin research on improving the PVA system
- by Lee, Jeong-Hwan Jan 27, 2022 05:43am
- Health insurance authorities have announced plans to place an order for research services to evaluate the PVA system and prepare improvement measures. It is said that it will further specify the targets for drug cuts and health insurance financial savings through PVA as large items. However, she replied that it is difficult to accept immediat
